Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Cavassini, Matthias"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 96
Tytuł:
Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells.
Autorzy:
Munoz O; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Banga R; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Schelling R; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Procopio FA; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Mastrangelo A; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Nortier P; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Ohmiti K; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Daraspe J; Electron Microscopy Facility, University of Lausanne, Lausanne, Switzerland.
Cavassini M; Services of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Fenwick C; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Perez L; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Perreau M; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2022 Jul 05; Vol. 18 (7), pp. e1010673. Date of Electronic Publication: 2022 Jul 05 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections*
T-Lymphocytes, Helper-Inducer*
B-Lymphocytes ; Humans ; T Follicular Helper Cells ; Virion
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.
Autorzy:
Mocroft A; CHIP, Rigshospitalet, Copenhagen, Denmark.; Centre for Clinical Research Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.
Miro JM; Hospital Clinic-IDIBAPS University of Barcelona, Barcelona, Spain.
Wandeler G; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Llibre JM; Infectious Diseases Unit & Fight AIDS Foundation, Hospital Germans Trias i Pujol, Badalona, Spain.
Boyd A; Stichting HIV Monitoring (SHM), Amsterdam, the Netherlands.; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
van Bremen K; Department of Medicine, University Hospital Bonn, Bonn, Germany.
Beniowski M; Diagnostics and Therapy for AIDS, Specialistic Hospital, Chorzów, Poland.
Mikhalik J; Crimean Republican AIDS Centre, Simferopol, Ukraine.
Cavassini M; Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Maltez F; Curry Cabral Hospital, Lisbon, Portugal.
Duvivier C; AP-HP-Necker Hospital, Infectious Diseases Department, Necker-Pasteur Infectiology Center, Paris, France.; University of Paris, INSERM U1016, Paris, France.; HU Imagine, Paris, France.; Institut Pasteur, Institut Pasteur Medical Center, Paris, France.
Uberti Foppa C; Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
Knysz B; Wroclaw Medical University, Wroclaw, Poland.
Bakowska E; Hospital for Infectious Diseases in Warsaw, Warsaw, Poland.
Kuzovatova E; Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology, Nizhny Novgorod, Russia.
Domingo P; Department of Infectious Diseases, Hospital of the Holy Cross and Saint Paul, Barcelona, Spain.
Zagalo A; Department of Infectious Diseases, Santa Maria University Hospital, Lisbon, Portugal.
Viard JP; Diagnostic and Therapeutic Center, Hôtel-Dieu, AP-HP, Paris, France.
Degen O; University Clinic Hamburg Eppendorf, Hamburg, Germany.
Milinkovic A; Chelsea and Westminster Hospital, London, UK.
Benfield T; Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark.
Peters L; CHIP, Rigshospitalet, Copenhagen, Denmark.
Pokaż więcej
Corporate Authors:
EuroSIDA study group
Źródło:
HIV medicine [HIV Med] 2022 Jul; Vol. 23 (6), pp. 585-598. Date of Electronic Publication: 2021 Dec 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections*/complications
Hepatitis B*/complications
Hepatitis B*/epidemiology
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/epidemiology
Neoplasms*/complications
DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV.
Autorzy:
Bick AG; Division of Genetic Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Popadin K; School of Life Sciences, École Polytechnique Fédérale de Lausanne, Station 19, 1015, Lausanne, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Thorball CW; School of Life Sciences, École Polytechnique Fédérale de Lausanne, Station 19, 1015, Lausanne, Switzerland.; Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Uddin MM; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Zanni MV; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Yu B; Human Genetics Center, Baylor College of Medicine, University of Texas Health Science Center, Houston, TX, USA.
Cavassini M; Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Rauch A; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Tarr P; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Schmid P; Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St.Gallen, St.Gallen, Switzerland.
Bernasconi E; Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland.
Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Libby P; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Boerwinkle E; Human Genetics Center, Baylor College of Medicine, University of Texas Health Science Center, Houston, TX, USA.
McLaren PJ; JC Wilt Infectious Diseases Research Centre, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Ballantyne CM; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Grinspoon S; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Natarajan P; Broad Institute of MIT and Harvard, Cambridge, MA, USA. .; Cardiovascular Research Center, Massachusetts General Hospital, 185 Cambridge Street, CPZN 3.184, Boston, MA, 02114, USA. .
Fellay J; School of Life Sciences, École Polytechnique Fédérale de Lausanne, Station 19, 1015, Lausanne, Switzerland. .; Swiss Institute of Bioinformatics, Lausanne, Switzerland. .; Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. .
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study
Źródło:
Scientific reports [Sci Rep] 2022 Jan 12; Vol. 12 (1), pp. 577. Date of Electronic Publication: 2022 Jan 12.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, American Recovery and Reinvestment Act; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Clonal Hematopoiesis*
HIV Infections/*complications
Adult ; Case-Control Studies ; Female ; HIV Infections/genetics ; HIV Infections/physiopathology ; Humans ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence.
Autorzy:
Kamal S; Community pharmacy, School of pharmaceutical sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.; Community pharmacy, Department of ambulatory care & community medicine, University of Lausanne, Lausanne, Switzerland.; Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.; University of California Institute for Prediction Technology, University of California, Los Angeles, CA, USA.
Urata J; Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.; University of California Institute for Prediction Technology, University of California, Los Angeles, CA, USA.
Cavassini M; Infectious Disease Service, Lausanne university hospital, University of Lausanne, Lausanne, Switzerland.
Liu H; Division of Public Health and Community Dentistry, School of Dentistry, University of California, Los Angeles, CA, USA.; Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA.; Department of Medicine, Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, CA, USA.
Kouyos R; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Bugnon O; Community pharmacy, School of pharmaceutical sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.; Community pharmacy, Department of ambulatory care & community medicine, University of Lausanne, Lausanne, Switzerland.
Wang W; University of California Institute for Prediction Technology, University of California, Los Angeles, CA, USA.; Department of Computer Science, University of California, Los Angeles, CA, USA.
Schneider MP; Community pharmacy, School of pharmaceutical sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.; Community pharmacy, Department of ambulatory care & community medicine, University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
AIDS care [AIDS Care] 2021 Apr; Vol. 33 (4), pp. 530-536. Date of Electronic Publication: 2020 Apr 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Machine Learning*
Anti-HIV Agents/*therapeutic use
Antiretroviral Therapy, Highly Active/*methods
HIV Infections/*drug therapy
Medication Adherence/*statistics & numerical data
Viral Load/*drug effects
Adult ; Algorithms ; CD4 Lymphocyte Count ; Cohort Studies ; Female ; HIV Infections/epidemiology ; HIV Infections/psychology ; Humans ; Male ; Medication Adherence/psychology ; Retrospective Studies ; Switzerland/epidemiology ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland.
Autorzy:
Darling KEA; Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.
Locatelli I; Division of Biostatistics and Quantitative Methods, Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland.
Benghalem N; Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.
Nadin I; Department of Clinical Neurosciences, Laboratory of Neuroimmunology, Research Centre of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland.
Calmy A; HIV Unit, Infectious Diseases Division, Medicine Specialties Department, Geneva University Hospital, University of Geneva, Geneva, Switzerland.
Gutbrod K; Division of Cognitive and Restorative Neurology, Department of Neurology, Inselspital Bern, Bern, Switzerland.
Hauser C; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Brugger P; Department of Neuropsychology, Neurology Clinic, University Hospital Zürich, Zürich, Switzerland.
Hasse B; Department of Infectious Diseases and Hospital Epidemiology, Universitätsspital Zurich, University of Zurich, Zurich, Switzerland.
Kovari H; Department of Infectious Diseases and Hospital Epidemiology, Universitätsspital Zurich, University of Zurich, Zurich, Switzerland.
Kunze U; Memory Clinic, Felix Platter Hospital, University Centre for Medicine of Aging, Basel, Switzerland.
Stoeckle M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Fux C; Infectious Diseases and Hospital Epidemiology Department, Kantonsspital Aarau, Aarau, Switzerland.
Rossi S; Neuropsychology Unit, Lugano Regional Hospital, Lugano, Switzerland.
Di Benedetto C; Infectious Diseases Division, Lugano Regional Hospital, Lugano, Switzerland.
Früh S; Neuropsychology Unit, Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Schmid P; Infectious Diseases and Hospital Epidemiology Division, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Tarr PE; University Department of Medicine, Kantonsspital Bruderholz, University of Basel, Bruderholz, Switzerland.
Daeppen JB; Service of Addiction Medicine, Lausanne University Hospital, Lausanne, Switzerland.
Du Pasquier R; Service of Neurology, Department of clinical neurosciences, Lausanne University Hospital, Lausanne, Switzerland.
Cavassini M; Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.
Pokaż więcej
Corporate Authors:
NAMACO Study Group, Swiss HIV Cohort Study
Źródło:
PloS one [PLoS One] 2021 Mar 02; Vol. 16 (3), pp. e0246579. Date of Electronic Publication: 2021 Mar 02 (Print Publication: 2021).
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Alcohol Drinking/*epidemiology
Anti-Retroviral Agents/*therapeutic use
HIV Infections/*drug therapy
Neurocognitive Disorders/*diagnosis
Aged ; Alcohol Drinking/psychology ; Female ; HIV Infections/psychology ; Humans ; Logistic Models ; Longitudinal Studies ; Male ; Mental Processes ; Middle Aged ; Neurocognitive Disorders/etiology ; Prospective Studies ; Switzerland
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Autorzy:
Sculier D; HIV/AIDS Unit, Department of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.; Private Practice Office, Geneva, Switzerland.
Wandeler G; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Yerly S; Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland.
Marinosci A; HIV/AIDS Unit, Department of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
Stoeckle M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, University of Basel, Switzerland.
Bernasconi E; Service of Infectious Diseases, Lugano Regional Hospital, Lugano, Switzerland.
Braun DL; Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Vernazza P; Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Cavassini M; Department of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.
Buzzi M; HIV/AIDS Unit, Department of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
Metzner KJ; Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Decosterd LA; Pharmacology Laboratory, Clinical Pharmacology Department, University of Lausanne, Lausanne, Switzerland.
Günthard HF; Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Schmid P; Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Limacher A; CTU Bern, University of Bern, Bern, Switzerland.
Egger M; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Calmy A; HIV/AIDS Unit, Department of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study (SHCS)
Źródło:
PLoS medicine [PLoS Med] 2020 Nov 10; Vol. 17 (11), pp. e1003421. Date of Electronic Publication: 2020 Nov 10 (Print Publication: 2020).
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections/*drug therapy
HIV Seropositivity/*drug therapy
HIV-1/*pathogenicity
Heterocyclic Compounds, 3-Ring/*therapeutic use
Oxazines/*therapeutic use
Piperazines/*therapeutic use
Pyridones/*therapeutic use
Adult ; Anti-HIV Agents/therapeutic use ; Emtricitabine/administration & dosage ; Emtricitabine/therapeutic use ; Female ; HIV-1/drug effects ; HIV-1/genetics ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Male ; Middle Aged ; Oxazines/adverse effects ; Piperazines/adverse effects ; Pyridones/adverse effects ; Switzerland
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Autorzy:
Courlet P; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Alves Saldanha S; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Cavassini M; Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Marzolini C; Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Choong E; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Csajka C; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Günthard HF; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland.; Institute of Medical Virology, Swiss National Reference Centre for Retroviruses, University of Zurich, Zurich, Switzerland.
André P; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Buclin T; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Desfontaine V; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Decosterd LA; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
Journal of mass spectrometry : JMS [J Mass Spectrom] 2020 Jun; Vol. 55 (6), pp. e4506. Date of Electronic Publication: 2020 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Retroviral Agents/*blood
Chromatography, High Pressure Liquid/*methods
Drug Monitoring/*methods
HIV Infections/*drug therapy
Tandem Mass Spectrometry/*methods
Amides ; Anti-Retroviral Agents/pharmacokinetics ; Anti-Retroviral Agents/therapeutic use ; Heterocyclic Compounds, 3-Ring ; Heterocyclic Compounds, 4 or More Rings/blood ; Heterocyclic Compounds, 4 or More Rings/pharmacokinetics ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; Limit of Detection ; Linear Models ; Piperazines ; Pyridones/blood ; Pyridones/pharmacokinetics ; Pyridones/therapeutic use ; Reference Standards ; Reproducibility of Results ; Rilpivirine/blood ; Rilpivirine/pharmacokinetics ; Rilpivirine/therapeutic use ; Triazoles/blood ; Triazoles/pharmacokinetics ; Triazoles/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
Autorzy:
Surial B; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Cavassini M; Division of Infectious Diseases, University Hospital of Lausanne, University of Lausanne, Lausanne, Switzerland.
Calmy A; Division of Infectious Diseases, Geneva University Hospital, University of Geneva, Geneva, Switzerland.
Fehr J; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Stöckle M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Bernasconi E; Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland.
Roth B; Division of Infectious Diseases, Cantonal Hospital of St Gallen, St Gallen, Switzerland.
Fux CA; Division of Infectious Diseases, Cantonal Hospital of Aarau, Aarau, Switzerland.
Kovari H; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Furrer H; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Rauch A; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Wandeler G; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland. .; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. .
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study
Źródło:
BMC infectious diseases [BMC Infect Dis] 2019 Oct 10; Vol. 19 (1), pp. 834. Date of Electronic Publication: 2019 Oct 10.
Typ publikacji:
Journal Article
MeSH Terms:
Adenine/*analogs & derivatives
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
Adenine/therapeutic use ; Adult ; Alanine ; CD4 Lymphocyte Count ; Cohort Studies ; Drug Interactions ; Female ; HIV Infections/complications ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/pathology ; Humans ; Male ; Middle Aged ; Risk Factors ; Switzerland ; Tenofovir/adverse effects ; Tenofovir/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017.
Autorzy:
Ruffieux Y; Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Lemsalu L; Department of Drug and Infectious Diseases Epidemiology, National Institute for Health Development, Tallinn, Estonia.; Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Aebi-Popp K; Division of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Calmy A; Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
Cavassini M; Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
Fux CA; Department of Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland.
Günthard HF; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Marzolini C; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Scherrer A; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Vernazza P; Department of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Keiser O; Institute of Global Health, University of Geneva, Geneva, Switzerland.
Egger M; Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.; Centre of Infectious Disease Epidemiology and Research (CIDER), University of Cape Town, Cape Town, South Africa.
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study and the Swiss National Cohort
Źródło:
Journal of the International AIDS Society [J Int AIDS Soc] 2019 Aug; Vol. 22 (8), pp. e25339.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Suicide*/statistics & numerical data
HIV Infections/*mortality
Adult ; Anti-Retroviral Agents/therapeutic use ; Antiretroviral Therapy, Highly Active/methods ; Cohort Studies ; Female ; HIV Infections/drug therapy ; Humans ; Male ; Middle Aged ; Risk Factors ; Switzerland/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement.
Autorzy:
Banga R; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Rebecchini C; Institute of Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Procopio FA; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Noto A; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Munoz O; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Ioannidou K; Institute of Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Fenwick C; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Ohmiti K; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Cavassini M; Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Corpataux JM; Service of Vascular Surgery, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
de Leval L; Institute of Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Pantaleo G; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.; Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Perreau M; Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2019 Jul 22; Vol. 15 (7), pp. e1007918. Date of Electronic Publication: 2019 Jul 22 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections/*immunology
HIV Infections/*virology
HIV-1/*genetics
HIV-1/*pathogenicity
Programmed Cell Death 1 Receptor/*metabolism
Anti-HIV Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage ; Cell Movement/immunology ; Cellular Microenvironment/immunology ; Coculture Techniques ; Dendritic Cells/immunology ; Dendritic Cells/virology ; Germinal Center/immunology ; Germinal Center/virology ; HIV Infections/drug therapy ; HIV-1/immunology ; Host Microbial Interactions/immunology ; Humans ; In Vitro Techniques ; Lymph Nodes/immunology ; Lymph Nodes/virology ; Programmed Cell Death 1 Ligand 2 Protein/metabolism ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Receptors, Immunologic/metabolism ; Receptors, Virus/metabolism ; T-Lymphocytes, Helper-Inducer/immunology ; T-Lymphocytes, Helper-Inducer/virology ; Transcription, Genetic ; Virulence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeted versus non-targeted HIV testing offered via electronic questionnaire in a Swiss emergency department: A randomized controlled study.
Autorzy:
Gillet C; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Darling KEA; Infectious Disease Service, Lausanne University Hospital, Lausanne, Switzerland.
Senn N; Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland.
Cavassini M; Infectious Disease Service, Lausanne University Hospital, Lausanne, Switzerland.
Hugli O; Emergency Department, Lausanne University Hospital, Lausanne, Switzerland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Mar 07; Vol. 13 (3), pp. e0190767. Date of Electronic Publication: 2018 Mar 07 (Print Publication: 2018).
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Computers, Handheld*
Diagnosis, Computer-Assisted/*methods
Emergency Medical Services/*methods
HIV Infections/*diagnosis
Mass Screening/*methods
Adolescent ; Adult ; Aged ; Cross-Over Studies ; Emergency Service, Hospital ; Female ; Humans ; Male ; Middle Aged ; Patient Acceptance of Health Care ; Risk Assessment/methods ; Surveys and Questionnaires ; Switzerland ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study.
Autorzy:
De Rossi N; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Dattner N; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Cavassini M; Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.
Peters S; Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Hugli O; Emergency Department, Lausanne University Hospital, Lausanne, Switzerland.
Darling KEA; Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2017 Jul 21; Vol. 12 (7), pp. e0180389. Date of Electronic Publication: 2017 Jul 21 (Print Publication: 2017).
Typ publikacji:
Journal Article
MeSH Terms:
AIDS Serodiagnosis*
Emergency Medical Services*
Patient Acceptance of Health Care*
Practice Patterns, Physicians'*
HIV Infections/*diagnosis
Academic Medical Centers ; Adult ; Attitude of Health Personnel ; Cross-Sectional Studies ; Early Diagnosis ; Emergency Service, Hospital ; Female ; HIV Infections/psychology ; Humans ; Male ; Prospective Studies ; Risk Factors ; Surveys and Questionnaires ; Switzerland
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Autorzy:
Sculier D; Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland. .
Gayet-Ageron A; Clinical Research Center and Division of Clinical Epidemiology, Department of Health and Community Medicine, University Hospital Geneva, Geneva, Switzerland.
Battegay M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Cavassini M; Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.
Fehr J; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Hirzel C; University Clinic of Infectious Diseases, University Hospital Bern, Bern, Switzerland.
Schmid P; Division of Infectious Diseases and Hospital Epidemiology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland.
Bernasconi E; Division of Infectious Diseases, Ospedale Regionale, Lugano, Switzerland.
Calmy A; Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland.
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study
Źródło:
BMC infectious diseases [BMC Infect Dis] 2017 Jul 06; Vol. 17 (1), pp. 476. Date of Electronic Publication: 2017 Jul 06.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms:
Anti-HIV Agents/*therapeutic use
Emtricitabine/*therapeutic use
HIV Infections/*drug therapy
Rilpivirine/*therapeutic use
Tenofovir/*therapeutic use
Adult ; Alkynes ; Antiretroviral Therapy, Highly Active/methods ; Benzoxazines/adverse effects ; CD4 Lymphocyte Count ; Cyclopropanes ; Drug Combinations ; Female ; HIV-1/genetics ; Humans ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
Autorzy:
Chereau F; Université Paris-Saclay, and Université Paris-Sud and Université de Versailles Saint-Quentin-en-Yvelines, and CESP, INSERM U1018, Kremlin-Bicêtre, France.
Madec Y; Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.
Sabin C; Research Department of Infection and Population Health, UCL, Royal Free Campus, Rowland Hill Street, London, United Kingdom.
Obel N; Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
Ruiz-Mateos E; Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medecine, Institute of Biomedecine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Chrysos G; Department of Medicine, Infectious Disease Unit, Tzaneio General Hospital of Piraeus, Piraeus, Greece.
Fidler S; Imperial College, London, United Kingdom.
Lehmann C; Department of Internal Medicine I, University of Cologne and German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
Zangerle R; Department of Dermatology and Venereology, Medical University Innsbruck, Innsbruck, Austria.
Wittkop L; University Bordeaux, ISPED, INSERM U1219-Bordeaux Population Health, INSERM, ISPED, Centre INSERM U1219-Bordeaux Population Health, CHU de Bordeaux, Pole de santé publique, Service d'information médicale, Bordeaux, France.
Reiss P; Stichting HIV Monitoring, Amsterdam, the Netherlands, and Department of Global Health, Academic Medical Center, Amsterdam, the Netherlands.
Hamouda O; Robert Koch Institute, Department for Infectious Disease Epidemiology, Berlin, Germany.
Estrada Perez V; Hospital Clinico San Carlos, IdISSC/Universidad Complutense, Madrid, Spain.
Leal M; Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medecine, Institute of Biomedecine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Mocroft A; Research Department of Infection and Population Health, UCL, Royal Free Campus, Rowland Hill Street, London, United Kingdom.
Garcia De Olalla P; Epidemiology Service, Public Health Agency of Barcelona, Barcelona and CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Ammassari A; Istituto Nazionale Malattie Infettive L. Spallanzani, IRCCS, Roma, Italy.
D'Arminio Monforte A; Infectious Diseases Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, University Hospital, Milan, Italy.
Mussini C; Clinic of Infectious diseases, University of Modena and Reggio Emilia, Modena, Italy.
Segura F; Infectious Diseases Service, Parc Taulí Hospital Universitario and Universidad Autónoma de Barcelona, Barcelona, Spain.
Castagna A; San Raffaele Vita Salute University, Milano, Italy.
Cavassini M; Infectious Diseases Service, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Grabar S; INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and UPMC Université Paris 06, and Université Paris Descartes, Hôpital Cochin Hôtel-Dieu Paris, Paris, France.
Morlat P; Service de médecine interne et maladies infectieuses, CHU de Bordeaux, Université de Bordeaux, Inserm U1219, Bordeaux, France.
De Wit S; Department of Infectious Diseases, St Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Lambotte O; Université Paris Sud, UMR 1184, Le Kremlin-Bicêtre, and CEA, DSV/iMETI, IDMIT, Fontenay-aux-Roses, and INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, France and Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie clinique, Le Kremlin-Bicêtre, France.
Meyer L; Université Paris-Saclay, and Université Paris-Sud and Université de Versailles Saint-Quentin-en-Yvelines, and CESP, INSERM U1018, Kremlin-Bicêtre, France.
Pokaż więcej
Corporate Authors:
HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD
Źródło:
PloS one [PLoS One] 2017 Apr 05; Vol. 12 (4), pp. e0173893. Date of Electronic Publication: 2017 Apr 05 (Print Publication: 2017).
Typ publikacji:
Journal Article
MeSH Terms:
CD4-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*immunology
HIV Infections/*immunology
Adult ; Anti-HIV Agents/therapeutic use ; Antiretroviral Therapy, Highly Active/methods ; CD4 Lymphocyte Count/methods ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/virology ; CD8-Positive T-Lymphocytes/drug effects ; Female ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV-1/immunology ; Humans ; Male ; Viral Load/drug effects ; Viral Load/immunology ; Viremia/drug therapy ; Viremia/immunology ; Viremia/virology ; Virus Replication/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy.
Autorzy:
Trickey A; School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.
May MT; School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.
Vehreschild J; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany.; Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Obel N; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Gill MJ; Division of Infectious Diseases, University of Calgary, Calgary, Canada.
Crane H; Center for AIDS Research, University of Washington, Seattle, WA, United States of America.
Boesecke C; Department of Internal Medicine, University of Bonn, Bonn, Germany.
Samji H; Epidemiology and Population Health Program, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, and Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Grabar S; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France.; INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France.; Université Paris Descartes et Assistance Publique-Hôpitaux de Paris, Groupe hospitalier Cochin Hôtel-Dieu, Paris, France.
Cazanave C; Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Bordeaux, F-33000, France.
Cavassini M; Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Shepherd L; Research Department of Infection and Population Health, UCL Medical School, London, United Kingdom.
d'Arminio Monforte A; Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Milan, Italy.
Smit C; Stichting HIV Monitoring, Amsterdam, the Netherlands.
Saag M; Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, United States of America.
Lampe F; Research Department of Infection and Population Health, UCL Medical School, London, United Kingdom.
Hernando V; Red de Investigación en Sida, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Avda. Monforte de Lemos, 5 28029, Madrid, Spain.
Montero M; La Fe Hospital, Valencia, Spain.
Zangerle R; Innsbruck Medical University, Innsbruck, Austria.
Justice AC; Yale University School of Medicine, New Haven, CT, United States of America, and VA Connecticut Healthcare System, West Haven, CT, United States of America.
Sterling T; Vanderbilt University School of Medicine, Nashville, TN, United States of America.
Miro J; Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.
Ingle S; School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.
Sterne JA; School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.
Pokaż więcej
Corporate Authors:
Antiretroviral Therapy Cohort Collaboration (ART-CC)
Źródło:
PloS one [PLoS One] 2016 Aug 15; Vol. 11 (8), pp. e0160460. Date of Electronic Publication: 2016 Aug 15 (Print Publication: 2016).
Typ publikacji:
Journal Article
MeSH Terms:
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
HIV Infections/*mortality
HIV-1/*physiology
Adolescent ; Adult ; Aged ; Anti-HIV Agents/pharmacology ; Demography ; Female ; HIV-1/drug effects ; Humans ; Male ; Middle Aged ; Risk Factors ; Survival Analysis ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland.
Autorzy:
Shilaih M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Marzel A; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Yang WL; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Scherrer AU; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Schüpbach J; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Böni J; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Yerly S; Laboratory of Virology, Geneva University Hospital, Geneva, Switzerland.
Hirsch HH; Department of Biomedicine-Petersplatz, University of Basel, Basel, Switzerland.
Aubert V; Division of Immunology and Allergy, University Hospital Lausanne, Lausanne, Switzerland.
Cavassini M; Division of Immunology, University Hospital Lausanne, Lausanne, Switzerland.
Klimkait T; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Vernazza PL; Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Bernasconi E; Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.
Furrer H; Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland.
Günthard HF; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Kouyos R; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study
Źródło:
Scientific reports [Sci Rep] 2016 Jun 14; Vol. 6, pp. 27580. Date of Electronic Publication: 2016 Jun 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Genotype*
Drug Resistance, Viral/*genetics
HIV Infections/*epidemiology
HIV-1/*genetics
Substance Abuse, Intravenous/*epidemiology
Adult ; Anti-HIV Agents/therapeutic use ; Cohort Studies ; Female ; HIV Infections/drug therapy ; HIV Infections/transmission ; HIV Infections/virology ; HIV-1/classification ; HIV-1/isolation & purification ; Heterosexuality ; Homosexuality, Male ; Humans ; Male ; Middle Aged ; Molecular Typing ; Multivariate Analysis ; Phylogeny ; Substance Abuse, Intravenous/drug therapy ; Substance Abuse, Intravenous/virology ; Switzerland/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.
Autorzy:
Young J; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland. .
Rickenbach M; Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland. .
Calmy A; Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland. .
Bernasconi E; Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland. .
Staehelin C; Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland. .
Schmid P; Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St Gallen, Switzerland. .
Cavassini M; Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland. Matthias.Cavassini@chuv.ch.
Battegay M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. .
Günthard HF; Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zürich, Zurich, Switzerland. .
Bucher HC; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland. .; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. .
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study
Źródło:
BMC infectious diseases [BMC Infect Dis] 2015 Sep 21; Vol. 15, pp. 382. Date of Electronic Publication: 2015 Sep 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections/*diagnosis
Viremia/*diagnosis
Adult ; Anti-HIV Agents/therapeutic use ; Cohort Studies ; Female ; HIV Infections/drug therapy ; HIV Infections/virology ; Humans ; Male ; Middle Aged ; Proportional Hazards Models ; RNA, Viral/blood ; Risk ; Viral Load ; Viremia/virology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Autorzy:
Kovari H; Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland.
Russmann S; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Ledergerber B; Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland.
Müller D; Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland.
Rotger M; Institute of Microbiology, University Hospital, Lausanne, Switzerland.
Velli P; Institute of Microbiology, University Hospital, Lausanne, Switzerland.
Cavassini M; Division of Infectious Diseases, University Hospital, Lausanne, Switzerland.
Ambrosioni J; Division of Infectious Diseases, University Hospital, Geneva, Switzerland.
Bregenzer A; Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland.
Stöckle M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basle, Switzerland.
Bernasconi E; Ospedale Regionale, Lugano, Switzerland.
Rauch A; University Clinic of Infectious Diseases, University Hospital Berne and University of Berne, Berne, Switzerland.
Speck RF; Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland.
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study
Źródło:
PloS one [PLoS One] 2015 Jul 28; Vol. 10 (7), pp. e0133879. Date of Electronic Publication: 2015 Jul 28 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Antiviral Agents/*therapeutic use
Coinfection/*blood
HIV Infections/*blood
Hepatitis C, Chronic/*blood
Interferon-alpha/*therapeutic use
Polyethylene Glycols/*therapeutic use
Ribavirin/*blood
Adult ; Coinfection/complications ; Coinfection/drug therapy ; Coinfection/virology ; Drug Monitoring ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Genotype ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV-1/drug effects ; Hepacivirus/drug effects ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology ; Humans ; Male ; Middle Aged ; Prospective Studies ; Recombinant Proteins/therapeutic use ; Ribavirin/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Autorzy:
Ciaffi L; HIV Unit, Department of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.
Cavassini M; Department of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland.
Genne D; Department of Infectious Diseases, La Chaux de Fonds Hospital, La Chaux de Fonds, Switzerland.
Delhumeau C; HIV Unit, Department of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.
Spycher Elbes R; HIV Unit, Department of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.
Hill A; Pharmacology Research Laboratories, Liverpool University, Liverpool, UK.
Wandeler G; Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland.
Fehr J; Division of Infectious Diseases & Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Stoeckle M; Department of Infectious Diseases, Basel Hospital, Basel, Switzerland.
Schmid P; Department of Infectious Diseases, St Gallen Hospital, St Gallen, Switzerland.
Hirschel B; HIV Unit, Department of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.
Montecucco F; Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland.; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy.; IRCCS Azienda Ospedaliera Universitaria San Martino - IST Instituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
Calmy A; HIV Unit, Department of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.
Pokaż więcej
Corporate Authors:
Swiss HIV Cohort Study
Źródło:
European journal of clinical investigation [Eur J Clin Invest] 2015 Jul; Vol. 45 (7), pp. 720-30.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV-1*
Cardiovascular Diseases/*prevention & control
Dyslipidemias/*drug therapy
HIV Infections/*drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Reverse Transcriptase Inhibitors/*therapeutic use
Adolescent ; Adult ; Aged ; Alkynes ; Benzoxazines/therapeutic use ; Biomarkers/metabolism ; Cyclopropanes ; Drug Substitution ; Female ; Humans ; Lipid Metabolism/physiology ; Male ; Middle Aged ; Nitriles ; Prospective Studies ; Pyridazines/therapeutic use ; Pyrimidines ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dynamics of HIV latency and reactivation in a primary CD4+ T cell model.
Autorzy:
Mohammadi P; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; Swiss Institute of Bioinformatics, Basel and Lausanne, Switzerland.
di Iulio J; Swiss Institute of Bioinformatics, Basel and Lausanne, Switzerland; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Muñoz M; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Martinez R; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Bartha I; Swiss Institute of Bioinformatics, Basel and Lausanne, Switzerland; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Cavassini M; Service of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Thorball C; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Fellay J; Swiss Institute of Bioinformatics, Basel and Lausanne, Switzerland; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Service of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Beerenwinkel N; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; Swiss Institute of Bioinformatics, Basel and Lausanne, Switzerland.
Ciuffi A; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; University of Lausanne, Lausanne, Switzerland.
Telenti A; Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2014 May 29; Vol. 10 (5), pp. e1004156. Date of Electronic Publication: 2014 May 29 (Print Publication: 2014).
Typ publikacji:
Journal Article
MeSH Terms:
HIV-1*
Virus Replication*
CD4-Positive T-Lymphocytes/*virology
HIV Infections/*virology
Virus Latency/*immunology
CD4-Positive T-Lymphocytes/immunology ; Cells, Cultured ; Humans ; Models, Immunological ; RNA, Viral/genetics ; Virus Integration/genetics ; Virus Latency/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 96

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies